The efficacy of tumor markers SCC, CEA, and CA-125 in patients with cervical cancer / 대한산부인과학회잡지

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the positive rate of squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and CA-125 according to clinical stage and histology. We also determine the rate of normalization of SCC after surgical and radiation therapy. RESULTS: In 222 patients with cervical cancer, the pre-treatment positive rate of SCC, CEA, and CA- 125 were 38.7%, 24.3%, and 19.8%, respectively. The positive rate of SCC by clinical stage were 12.9% for stage I, 60.5% for stage II, 88.2% for stage III, and 87.5% for stage IV. The positive rate of CEA by stage were 7.8% for stage I, 36.4% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rate of CA-125 by stage were 5.9% for stage I, 23.3% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. According to histology, the positive rate of SCC (39.8%) was more significantly higher than the positive rates of other tumor makers in squamous cell carcinoma of the uterine cervix. The positive rate of CA-125 was higher than the positive rate of other tumor markers in adenocarcinoma and adenosquamous carcinoma of the uterine cervix, but it was not statistically significant difference. CONCLUSION: SCC have been shown to be higher positive rate than any other tumor markers in patients with cervical cancer. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. Concomitant measurement of SCC, CEA, and CA-125 may be more useful than measurement of SCC alone, and further study was needed.